FDA Issues Single Observation to Cipla’s Goa Facility Post-Inspection

Cipla announced that the United States Food and Drug Administration (FDA) conducted an inspection at its wholly-owned subsidiary, Medispray Laboratories Private Ltd, situated in Kundaim, Goa, between 14th and 20th January 2025. The inspection concluded with the issuance of a single observation under Form 483.

Details of the FDA Inspection

The FDA conducted a detailed inspection of Medispray Laboratories Private Ltd, Cipla’s Goa-based manufacturing facility, over six days. The company revealed this development in a regulatory filing, confirming that the inspection identified one observation, which was communicated through Form 483.

Cipla expressed its commitment to addressing the FDA’s observation in full compliance with the stipulated timelines. The company will collaborate closely with the FDA to ensure that the necessary corrective measures are implemented effectively.

Understanding Form 483

Form 483 is a document issued by FDA inspectors at the conclusion of an inspection to highlight observations related to a facility’s compliance with Good Manufacturing Practices (GMP). These observations are explained to the company during a closing conference.

It is important to note that Form 483 does not reflect the FDA’s final determination on the facility’s compliance status. Companies are required to respond to the FDA within 15 days, outlining their action plan to resolve the identified issues.

Cipla Share Performance 

As of January 21, 2025, 11:00 AM, the shares of Cipla are trading at ₹1,437.95 per share with a decline of 0.52% from its previous day’s closing price.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.